Bank of Montreal Can Sells 2,988,111 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Bank of Montreal Can lowered its position in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 78.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 845,068 shares of the company's stock after selling 2,988,111 shares during the period. Bank of Montreal Can owned about 0.23% of Bausch Health Companies worth $6,823,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Wells Fargo & Company MN grew its stake in Bausch Health Companies by 7.9% in the 4th quarter. Wells Fargo & Company MN now owns 25,907 shares of the company's stock valued at $209,000 after purchasing an additional 1,896 shares during the period. ExodusPoint Capital Management LP purchased a new stake in Bausch Health Companies during the fourth quarter worth about $1,594,000. Cinctive Capital Management LP raised its position in Bausch Health Companies by 165.6% in the fourth quarter. Cinctive Capital Management LP now owns 222,348 shares of the company's stock worth $1,792,000 after acquiring an additional 138,638 shares during the period. Trexquant Investment LP grew its position in shares of Bausch Health Companies by 155.4% during the 4th quarter. Trexquant Investment LP now owns 298,334 shares of the company's stock valued at $2,405,000 after acquiring an additional 181,532 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Bausch Health Companies by 12.5% during the 4th quarter. Geode Capital Management LLC now owns 715,570 shares of the company's stock worth $5,767,000 after purchasing an additional 79,488 shares during the last quarter. 78.65% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

BHC has been the subject of a number of recent research reports. Royal Bank of Canada decreased their target price on Bausch Health Companies from $9.00 to $8.50 and set a "sector perform" rating for the company in a research report on Monday, April 7th. Jefferies Financial Group restated a "hold" rating and issued a $8.00 price objective (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $7.17.

Bausch Health Companies Stock Up 13.9 %

NYSE:BHC traded up $0.63 during mid-day trading on Friday, hitting $5.13. 9,205,650 shares of the stock traded hands, compared to its average volume of 2,710,622. The business's 50-day moving average price is $6.37 and its 200 day moving average price is $7.44. The company has a market cap of $1.89 billion, a PE ratio of -42.70, a price-to-earnings-growth ratio of 0.37 and a beta of 0.43. Bausch Health Companies Inc. has a 12-month low of $3.96 and a 12-month high of $9.85.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.44). The firm had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. Analysts anticipate that Bausch Health Companies Inc. will post 4.41 earnings per share for the current fiscal year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.